- Tryp Therapeutics (TRYP) is filing two new provisional patent applications
- One patent application is for the use of psilocybin for the treatment of patients with fibromyalgia
- The other expands the IP related to the company’s development of TRP-8803
- Tryp Therapeutics (TRYP) is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways
- Tryp Therapeutics (TRYP) is down today, trading at C$0.15 at 4:17 pm ET
Tryp Therapeutics (TRYP) is filing two new provisional patent applications.
One patent application is for the use of psilocybin for the treatment of patients with fibromyalgia, and the other expands the IP related to the company’s development of TRP-8803.
Jim Gilligan, CEO of Tryp Therapeutics, says:
“Tryp is taking an innovative approach to expand treatment alternatives for patients suffering from nociplastic pain and eating disorders who haven’t had success with currently approved drugs. We are methodically expanding our patent portfolio and remain committed to developing a combined psychedelic and psychotherapy treatment for patients suffering the debilitating effects of conditions such as fibromyalgia and Binge Eating Disorder.”
The company is preparing for a Phase 2a clinical trial in collaboration with the University of Michigan to investigate the safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia. The clinical studies are expected to reinforce the positive preclinical results obtained by Tryp in an animal model of nociplastic pain. Once issued, the new patent will provide Tryp with Intellectual Property Protection for fibromyalgia utilizing its psilocybin-based candidates.
Tryp is utilizing TRP-8802 to evaluate the use of psilocybin-related compounds in certain neuropsychiatric disorders in early-stage trials. Tryp’s leading drug candidate, TRP-8803, which is being developed concurrently, will be studied in subsequent trials where efficacy is indicated. TRP-8803 includes a unique formulation and delivery system to enhance the positive effects of psilocybin and psilocybin-related compounds while markedly reducing the limitations of psilocybin dosed through other routes of administration, including oral, nasal and sublingual.
The second provisional patent will expand the IP supporting TRP-8803 Tryp’s proprietary psilocybin-based product. The focus of the provisional patent application involves the development of salt forms and co-formers that improve the chemical properties of TRP-8803, thereby improving its stability and suitability for TRP-8803’s novel formulation and route of administration.
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.
Tryp Therapeutics (TRYP) is down today, trading at C$0.15 at 4:17 pm ET.
